Reversing the standard approved dose levels of nivolumab (Opdivo) and ipilimumab (Yervoy) in metastatic melanoma led to less ...

Investigators reported extended 5-year follow-up data from the CheckMate 274 trial including exploratory MIBC and circulating tumor (ct)DNA data.

BMY shares have surged in the past six months, driven by Opdivo, Reblozyl and a guidance raise, as growth drugs offset ...

Based on phase 3 trial data, the FDA accepted an sBLA for nivolumab plus AVD for untreated stage III or IV classical Hodgkin lymphoma.

HOUSTON, JANUARY 9, 2026 ― At The University of Texas MD Anderson Cancer Center , research breakthroughs are made possible through seamless ...

Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the ...

Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference Reaching more metastatic uveal melanoma patients ...

Biocon Biologics to launch Trastuzumab, Nivolumab, Pembrolizumab biosimilars for cancer. Expanding oncology portfolio.

Trastuzumab, Nivolumab and Keytruda: Our Bureau, Bengaluru Wednesday, January 7, 2026, 11:30 Hrs [IST] Biocon Biologics, ...

Pivotal Phase 3 trial of MO-03 builds on prior studies that demonstrated enhanced immunotherapy benefit without added ...

Biocon Biologics plans to introduce three oncology biosimilars, enhancing its cancer treatment portfolio. They will unveil ...

These products are among the largest oncology biologics expected to lose exclusivity over the next five years.